- $4.98m
- $5.20m
- $15.71m
- 28
- 51
- 33
- 30
Growth & Value
12m Forecast Rolling | Industry | Market | |
---|---|---|---|
PE Ratio (f) | n/a | ||
PEG Ratio (f) | n/a | ||
EPS Growth (f) | n/a | ||
Dividend Yield (f) | n/a |
Valuation (ttm) | Industry | Market | |
---|---|---|---|
Price to Book Value | 2.77 | ||
Price to Tang. Book | 6.81 | ||
Price to Free Cashflow | n/a | ||
Price to Sales | 0.32 | ||
EV to EBITDA | n/a |
Shareholder Activity
Type | Buy / Hold / Sell |
---|---|
Institutions | |
Directors | |
Community |
Guru Screens
Quality
Name | Industry | Market | |
---|---|---|---|
Return on Capital | -120.46% | ||
Return on Equity | -101.92% | ||
Operating Margin | -13.94% |
Financial Summary
Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
---|---|---|---|---|---|---|---|---|---|
Total Revenue | $m | 24.43 | 20.05 | 16.2 | 16 | 15.71 | n/a | n/a | -21.8% |
Operating Profit | m | ||||||||
Net Profit | m | ||||||||
EPS Reported | |||||||||
Diluted Normalised EPS | |||||||||
EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
PE Ratio | x | ||||||||
PEG | |||||||||
Profitability | |||||||||
Operating Margin | % | ||||||||
ROA | % | ||||||||
ROCE | % | ||||||||
ROE | % | ||||||||
Cashflow | |||||||||
Op. Cashflow ps | |||||||||
Capex ps | |||||||||
Free Cashflow ps | |||||||||
Dividends | |||||||||
Dividend ps | |||||||||
Dividend Growth | % | ||||||||
Dividend Yield | % | ||||||||
Dividend Cover | x | ||||||||
Balance Sheet | |||||||||
Cash etc | m | ||||||||
Working Capital | m | ||||||||
NFA | m | ||||||||
Net Debt | m | ||||||||
Book Value | m | ||||||||
Diluted Weighted Average Shares | m | ||||||||
Book Value ps |
Other Ratios
Leverage (ttm) | Total | - Intang | + Pension |
---|---|---|---|
Gross Gearing | |||
Net Gearing | |||
Cash / Assets |
Liquidity (ttm) | |
---|---|
Curr. Ratio | |
Quick Ratio | |
Interest Cov. |
Efficiency (ttm) | |
---|---|
Asset Turnover | |
Recs Turnover | |
Stock Turnover |
Recent History
Latest interim period vs. prior period | Industry | Market | |
---|---|---|---|
Sales Growth | |||
EPS Growth |
3yr Compound Annual Growth Rate | Industry | Market | |
---|---|---|---|
Sales CAGR | |||
EPS CAGR | |||
DPS CAGR |
Profile Summary
CV Sciences, Inc. is a consumer wellness company specializing in nutraceuticals and plant-based foods. The Company develops, manufactures, markets and sells herbal supplements, CBD products and plant-based food products under +PlusCBD, +PlusHLTH, Cultured Foods, and Lunar Fox brands in the healthcare market sector, including nutraceutical, beauty care, specialty foods, and pet products. Its hemp extracts, and other science-backed, natural ingredients and products are sold through a range of sales channels from business-to-business (B2B) to business-to-consumer (B2C). Its +PlusCBD line of products are available in softgels, tinctures, topicals, and gummies. Its Cultured Foods and Lunar Fox cater to individuals seeking vegan, gluten-free, or flexitarian options for a nutritious and satisfying culinary experience. Its +PlusHLTH is a line of cannabinoid-free supplements delivering targeted formulations for optimized health, improved performance and increased vitality.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- July 26th, 2013
- Public Since
- October 4th, 2018
- No. of Shareholders
- 41
- No. of Employees
- 47
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
Pink Sheets on Nasdaq
- Shares in Issue
- 184,263,663

- Address
- 9530 PADGETT STREET, SUITE 107, SAN DIEGO, 92126
- Web
- https://cvsciences.com/
- Phone
- Auditors
- Haskell & White LLP
Upcoming Events for CVSI
CV Sciences Inc Annual Shareholders Meeting
CV Sciences Inc Annual Shareholders Meeting
Q2 2025 CV Sciences Inc Earnings Release
Similar to CVSI
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
As of Today at 20:09 UTC, shares in CV Sciences are trading at $0.03. This share price information is delayed by 15 minutes.
Shares in CV Sciences last closed at $0.03 and the price had moved by -30.14% over the past 365 days. In terms of relative price strength the CV Sciences share price has underperformed the S&P500 Index by -35.22% over the past year.
The overall consensus recommendation for CV Sciences is Hold. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreCV Sciences does not currently pay a dividend.
CV Sciences does not currently pay a dividend.
CV Sciences does not currently pay a dividend.
To buy shares in CV Sciences you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $0.03, shares in CV Sciences had a market capitalisation of $4.98m.
Here are the trading details for CV Sciences:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: CVSI
Based on an overall assessment of its quality, value and momentum CV Sciences is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in CV Sciences is $0.05. That is 85.19% above the last closing price of $0.03.
Analysts covering CV Sciences currently have a consensus Earnings Per Share (EPS) forecast of for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like CV Sciences. Over the past six months, its share price has underperformed the S&P500 Index by -43.6%.
As of the last closing price of $0.03, shares in CV Sciences were trading -33.56% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The CV Sciences PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.03.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on CV Sciences' directors